Roche ’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors

Roche announced today that new data from the ongoing Hemlibra ® (emicizumab) clinical development programme were presented at the 59th American Society of Hematology (ASH) Annual Meeting.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news